You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 8,546,143


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,546,143
Title:Compositions and methods for inhibiting expression of a target gene
Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is substantially identical to at least a part of a target gene and which is no more than 49, preferably less than 25, nucleotides in length, and which comprises a complementary (antisense) RNA strand having a 1 to 4 nucleotide overhang at the 3'-end and a blunt 5'-end. The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene, at low dosages (i.e., less than 5 milligrams, preferably less than 25 micrograms, per kg body weight per day). The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
Inventor(s): Kreutzer; Roland (Weidenberg, DE), Limmer; Stefan (Kulmbach, DE), Limmer; Sylvia (Kulmbach, DE), Hadwiger; Philipp (Bayreuth, DE)
Assignee: Alnylam Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/894,018
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 8,546,143

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,546,143

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 00 586Jan 9, 2001
Germany101 55 280Oct 26, 2001
Germany10 158 411Nov 29, 2001
Germany101 60 151Dec 7, 2001

International Family Members for US Patent 8,546,143

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 222953 ⤷  Try a Trial
Austria 297463 ⤷  Try a Trial
Austria 328075 ⤷  Try a Trial
Austria 418610 ⤷  Try a Trial
Austria 460481 ⤷  Try a Trial
Australia 2002229701 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.